Path ID: DB00197_MESH_D003924_2
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D000077288 | Troglitazone | Drug |
| UniProt:P37231 | Peroxisome proliferator-activated receptor gamma | Protein |
| InterPro:IPR000003 | Retinoid X receptor/HNF4 | GeneFamily |
| UniProt:P15090 | Fatty acid-binding protein, adipocyte | Protein |
| GO:0060612 | adipose tissue development | BiologicalProcess |
| MESH:D005230 | Fatty Acids, Nonesterified | ChemicalSubstance |
| HP:0000855 | Insulin resistance | PhenotypicFeature |
| MESH:D003924 | Diabetes Mellitus, Type 2 | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Troglitazone | INCREASES ACTIVITY OF | Peroxisome Proliferator-Activated Receptor Gamma |
| Peroxisome Proliferator-Activated Receptor Gamma | MOLECULARLY INTERACTS WITH | Retinoid X Receptor/Hnf4 |
| Retinoid X Receptor/Hnf4 | INCREASES ACTIVITY OF | Fatty Acid-Binding Protein, Adipocyte |
| Fatty Acid-Binding Protein, Adipocyte | POSITIVELY REGULATES | Adipose Tissue Development |
| Adipose Tissue Development | NEGATIVELY CORRELATED WITH | Fatty Acids, Nonesterified |
| Fatty Acids, Nonesterified | CONTRIBUTES TO | Insulin Resistance |
| Insulin Resistance | MANIFESTATION OF | Diabetes Mellitus, Type 2 |
Comment: Troglitazone was withdrawn from the United States market in 2000 due to risk of hepatotoxicity.
Reference: